Bispebjerg Hospital
- Address
- Nielsine Nielses vej 11, 2400 Copenhagen, Denmark
Migraine Prevention Research
The Department of Neurology at Bispebjerg Hospital is evaluating new preventive strategies for migraine in adults who have not responded adequately to existing oral therapies.
- Assessment of rimegepant efficacy for reducing monthly migraine days
- Comparison with placebo to determine therapeutic benefit
- Monitoring tolerability in patients with prior preventive treatment failure
These investigations aim to improve long‑term control of migraine attacks and offer an alternative for patients with limited options.
Acute Migraine Treatment Research
Researchers at Bispebjerg Hospital are conducting trials to test rapid‑acting therapy for migraine attacks, especially in individuals unsuitable for triptan medications.
- Evaluation of pain relief within two hours after dosing
- Direct comparison of rimegepant versus placebo for acute symptom control
- Safety and tolerability profiling in a real‑world patient population
The goal is to provide an effective, well‑tolerated option for fast relief of migraine symptoms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bispebjerg Hospital
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Guselkumab and Golimumab Combination Therapy in Moderate to Severe Crohn's Disease: A Phase 2b Randomized Controlled Trial | Janssen Cilag International | Phase II | Not Recruiting | Nov 2022 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rimegepant | 2 | Unknown | 2023-03-14 | 2023-03-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.